# Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

> **NCT01370902** · PHASE1 · COMPLETED · sponsor: **Innate Pharma** · enrollment: 92 (actual)

## Conditions studied

- Inflammation
- Rheumatoid Arthritis

## Interventions

- **DRUG:** NNC 0141-0000-0100
- **DRUG:** placebo
- **DRUG:** NNC 0141-0000-0100
- **DRUG:** placebo
- **DRUG:** NNC 0141-0000-0100
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01370902
- **Lead sponsor:** Innate Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01370902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01370902, "Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01370902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*